In the human placenta, embryo-derived trophoblasts aggressively invade maternal spiral arteries and transform the arteries to low-resistance large-caliber vessels. This process, which ensures adequate placental perfusion, is called maternal vascular remodeling. Histological examination showed deposition of maternal platelets in the trophoblast aggregates formed in the spiral arteries. Several lines of evidence suggest that these platelets are activated. Soluble factors released from the activated platelets, as a whole, enhanced invasive capacity of isolated trophoblasts in vitro. These fi ndings suggest the importance of nonhemostatic platelet function in maternal vascular remodeling. In contrast, gene knockout studies suggest that maternal platelet defects are compatible with successful pregnancy in mice. Moreover, pregnant women with severe platelet defects usually accomplish an uneventful pregnancy. Thus, promotion of endovascular trophoblast infi ltration by maternal platelets might not be the only mechanism that regulates maternal vascular remodeling. The maternal vascular remodeling is an essential component of human reproduction and should be secured by several complementary mechanisms. Future studies should aim to elucidate other mechanisms that could regulate endovascular trophoblast infi ltration.
Introduction
In the human placenta, cytotrophoblasts show two distinct patterns of differentiation (Fig. 1) . In fl oating villi, cytotrophoblasts differentiate into syncytiotrophoblast and form the syncytial layer, where exchange of gas and nutrients takes place. At villus-anchoring sites, cytotrophoblasts differentiate into extravillous trophoblasts and form the stratifi ed structure called the cell column. After losing proliferative activity and acquiring invasive activity in the cell column, 1 extravillous trophoblasts begin to invade decidual tissue (interstitial trophoblasts) or maternal blood vessels (endovascular trophoblasts).
Endovascular trophoblasts destroy the muscular linings and replace the endothelium of the maternal spiral arteries, transforming them from small resistant vessels to fl accid large-caliber vessels. This process is called maternal vascular remodeling. The maternal vascular remodeling ensures adequate placental perfusion and contributes to establishment of a successful pregnancy. 2 In fact, endovascular trophoblast invasion is limited to superfi cial deciduas, and the myometrial segments remain narrow in cases of preeclampsia and/ or intrauterine growth restriction. 3 Vascular infi ltration by endovascular trophoblast is a unique phenomenon in the primate placenta. 4 Moreover, in most nonhuman primates, vascular remodeling is restricted to the decidua, which in humans has to be considered as pathological. Lack of a proper experimental model animal has hampered analysis of endovascular trophoblast invasion, and the mechanism is still largely unknown.
Platelets in human placentation
What directs extravillous trophoblasts toward the maternal spiral arteries? It is intuitive to consider that some factor(s) derived from the endothelium or blood constituents direct this movement. Relatively high oxygen tension in maternal arteries promotes trophoblast differentiation toward an invasive phenotype, which could be one of the mechanisms that facilitate endovascular trophoblast invasion. 5 This hypothesis is derived from the fi ndings that isolated cytotrophoblasts cultured under hypoxic conditions (2% O 2 ) continued proliferating, whereas those cultured in 20% O 2 stopped proliferating and differentiated to an invasive phe-notype. Another candidate that facilitates endovascular trophoblast invasion could be maternal platelets. 6 Histological examination of the human placental bed revealed that maternal platelets are trapped by endovascular trophoblast aggregates that are formed inside the lumen of the spiral arteries. These platelets were attached to collagen deposited around endovascular trophoblasts, suggesting that these platelets are activated. Indeed, these platelets expressed P-selectin. P-selectin is one of the activation markers of platelets that binds to P-selectin glycoprotein ligand-1 (PSGL-1) on the surface of neutrophils, leading to recruitment and activation of the neutrophils. The activated neutrophils, in turn, release platelet-activating factor (PAF) that promotes platelet aggregation. 7 In vitro, coculturing with platelets that were activated by collagen induced matrigel invasion of extravillous trophoblasts isolated from early human placental tissue. After 48-h culture, most of the isolated extravillous trophoblasts exhibit elongated spindleshaped morphology mimicking interstitial trophoblasts, whereas they are transformed to a round-shaped morphology mimicking endovascular trophoblasts after 48-h coculture with platelets (Fig. 2) . The round-shaped cells share similar molecular properties with endovascular trophoblasts in vivo, such as upregulation of integrin α1 and CCR1. 8, 9 These changes do not require direct contact of platelets and isolated extravillous trophoblasts, suggesting that some soluble factor(s) derived from the activated maternal platelets direct trophoblast invasion toward the maternal arteries and induce differentiation toward an endovascular phenotype.
Then, what are the platelet-derived soluble factors that enhance trophoblast invasion? Besides regulating hemostasis, platelets contain a number of bioactive peptides, including growth factors (EGF, VEGF, PDGF-B, TGF-β1, IGF-1, HGF, bFGF), cytokines (soluble CD40 ligand), chemokines (RANTES, βTG, PF4), and bioactive phospholipids (S1P). These mediators are stored in platelet granules and released upon stimulation. 10 The effect of platelet-conditioned medium to promote invasion of the isolated extravillous trophoblasts was completely abrogated by heat treatment but not by charcoal stripping. 9 This fi nding suggests that some growth factors, cytokines, or chemokines, but not bioactive phospholipids, contribute to the invasion-promoting effect of platelets. Immunocytochemistry revealed that iso- lated extravillous trophoblasts express a chemokine receptor, CCR1. Matrigel invasion assay revealed that RANTES, one of the CCR1 ligands, enhances invasion of isolated extravillous trophoblasts, indicating that CCR1 expressed on isolated extravillous trophoblasts is a functional receptor. Interestingly, immunohistochemistry of the placental bed showed that CCR1 is predominantly expressed from the cell column through endovascular trophoblasts. These fi ndings suggest that circulating maternal platelets are trapped by endovascular trophoblast aggregates and activated to release CCR1 ligands, which in turn attracts CCR1-positive extravillous trophoblasts into maternal spiral arteries to encourage the vascular remodeling (Fig. 3) .
In this theory, activation of platelets in the spiral arteries requires the preexistence of endovascular trophoblast aggregates. In this respect, the platelet is not a primary initiator of extravillous trophoblast invasion into the spiral arteries; rather, it might provide a positive feedback mechanism that facilitates endovascular trophoblast infi ltration.
Platelets in mouse placentation
Gene knockout has generated several mice lineages that have quantitative or qualitative platelet defects. The transcription factor NF-E2 is essential for megakaryopoiesis, and NF-E2-defi cient mice have severe quantitative platelet defects.
11,12 NF-E2-null murine embryos are able to complete intrauterine life, although they show signifi cant growth restriction at birth. The growth restriction is associated with abnormal vascularization of the labyrinthine layer in NF-E2-null placenta. Because the number of blood vessels in the labyrinthine layer is not reduced, abnormal vascularization is considered to result from failure in the maturation of preexisting vessels. These fi ndings indicate that embryonic platelets are required for normal placentation. 13 In mice lacking the α-subunit of the heterotrimeric guanine nucleotide-binding protein Gq (Gαq), platelet count is normal, but these platelets cannot be activated in vitro with physiological agonists including thrombin, ADP, and collagen.
14 In contrast to NF-E2-null mice, vascularization of Gαq-null placenta is not affected, suggesting that hemostatic platelet function is not required for normal placentation. In other words, nonhemostatic function of platelets, which is only revealed in mice with quantitative platelet defect, is essential for the maturation of the fetus-derived vessels in the placenta. 13 Both quantitatively and qualitatively, platelet-defi cient mice are able to complete intrauterine development, and some of them even survive to reproductive age. These adult female mice allow analysis of possible effects of maternal platelet defect on placentation. In contrast to NF-E2-null embryos, the litter size of NF-E2-null mothers is not reduced so long as the embryo has a normal platelet count. Detailed analysis of the placental histology showed that massive placental hemorrhage occurs in approximately half of the placentas of NF-E2-null mothers most probably consequent to maternal bleeding diathesis. 15 Thus, maternal platelets are not required for normal murine placentation.
Platelets and human pathological pregnancies
Primary hemostasis begins immediately after endothelial disruption. The exposed subendothelial collagen recruits circulating von Willebrand factor, which binds to the platelet surface glycoprotein Ib-IX-V complex and thus mediates the contact between collagen and platelets. Collagen- Fig. 3 . Illustration of possible chemokine gradient produced by platelets in spiral arteries and its estimated effects on endovascular trophoblast infi ltration. In the spiral artery undergoing vascular remodeling, platelets are deposited among the endovascular trophoblasts. These platelets are likely to have been activated by extracellular matrix secreted from endovascular trophoblasts and to have released various soluble factors including CCR1 ligands, forming a local chemokine gradient. The chemokine gradient directs CCR1-positive extravillous trophoblasts into the spiral artery, providing a positive feedback cascade for trophoblastic arterial infi ltration. Note that CCR1 is expressed from the cell column through endovascular trophoblasts activated platelets form pseudopods that stretch out to cover the injured surface and express receptors for fi brinogen, which mediates primary platelet aggregation. Next, bioactive substances such as thromboxane A2 are released from the activated platelets (platelet degranulation) and further activate surrounding platelets. These activated platelets express glycoprotein IIb-IIIa complex that can bind to von Willebrand factor. Secondary platelet aggregation is mediated by interaction between von Willebrand factor and the glycoprotein IIb-IIIa complex, leading to primary thrombus formation. In secondary hemostasis, a coagulation cascade effi ciently progresses on the phospholipid exposed on the surface of the aggregated platelets to solidify the primary thrombus (secondary thrombus formation).
Low-dose aspirin has been used worldwide to prevent placenta-mediated obstetrical complications such as recurrent pregnancy loss, intrauterine growth restriction, and preeclampsia. 16 Aspirin inhibits platelet cyclooxygenase to suppress synthesis of thromboxane A2, which induces secondary platelet aggregation and systemic vasoconstriction. Thus, theoretically, aspirin can inhibit thrombus formation in the placenta to help maintain placental blood fl ow as well as ameliorate hypertension in preeclampsia. In fact, a recent meta-analysis established a moderate but consistent preventative effect of low-dose aspirin therapy on preeclampsia. 17 Because aspirin does not interfere with platelet adhesion to collagen or subsequent platelet degranulation, platelet release of bioactive soluble factors other than thromboxane A2 should be maintained during low-dose aspirin therapy. Therefore, in terms of maternal vascular remodeling, aspirin does no harm to endovascular trophoblast invasion enhanced by platelet-derived soluble factors.
Secondary thrombus formation generally ensues after platelet activation. Given that maternal platelets trapped by the endovascular trophoblasts are activated, it seems peculiar that no fi brin deposition is detected among the endovascular trophoblast aggregates. Although the actual mechanism for this discrepancy remains to be elucidated, abundant thrombomodulin 18 and tissue-and urokinase-type plasminogen activators [19] [20] [21] expressed by trophoblasts could inhibit the coagulation cascade and/or facilitate rapid degradation of the fi brin at the surface of the endovascular trophoblasts. In pathological pregnancies such as preeclampsia, it is fascinating to consider that inhibitory mechanism against the secondary thrombus formation around the endovascular trophoblasts is defective, thus leading to excessive placental thrombosis. In this situation, aspirin could be particularly benefi cial, because it can inhibit platelet secondary aggregation that triggers the initiation of the coagulation cascade without affecting endovascular trophoblast invasion.
Bernard-Soulier syndrome is characterized by defi ciency of platelet glycoprotein Ib-IX-V complex that mediates contact of platelets with collagen. 22 In this pathological condition, collagen activation of platelets is severely impaired and most of the patients exhibit spontaneous bruising, epistaxis, and bleeding after minor trauma. In pregnancy, entrapment of maternal platelets by collagen-deposited endovascular trophoblasts and subsequent activation should be restricted, resulting in insuffi cient maternal vascular remodeling. However, pregnant women with BernardSoulier syndrome as well as those with congenital thrombocytopenia generally complete an uneventful pregnancy despite an increased risk of postpartum hemorrhage. [23] [24] [25] This fi nding suggests that maternal platelets are not an essential component of the human placentation process, including maternal vascular remodeling. Although in vitro data suggest the importance of maternal platelets in endovascular trophoblast infi ltration, their actual role in vivo still needs to be defi ned.
Conclusion and future direction
In the human placenta, maternal platelets are deposited in trophoblast clusters that have invaded the uterine spiral arteries. These platelets are likely to be activated and release various soluble factors, which as a whole enhance the invasive capacity of extravillous trophoblasts in vitro. Thus, maternal platelets might be a candidate that attracts extravillous trophoblasts into the spiral arteries and encourages maternal vascular remodeling. As demonstrated in gene-knockout mice with quantitative or qualitative platelet defects, however, maternal platelets are not required for murine placentation. The fact that pregnant women with severe platelet defects can achieve an uneventful pregnancy suggests that maternal platelets are not an essential component of human placentation.
The maternal vascular remodeling that ensures adequate placental perfusion is an essential component of human reproduction and should be secured by several complementary mechanisms. In this respect, promotion of endovascular trophoblast infi ltration by maternal platelets could be one of the mechanisms that regulate vascular remodeling, although the vascular remodeling might occur in the absence of maternal platelets.
Precise characterization of endovascular trophoblasts, which is a crucial step for clarifi cation of the mechanism(s) of maternal vascular remodeling, has been hampered by extreme diffi culty in their isolation from the human placenta. As already mentioned, co-culture with platelets could induce differentiation of isolated extravillous trophoblasts toward the endovascular phenotype in vitro. These endovascular-like trophoblasts are potentially useful to characterize endovascular trophoblasts, leading to identifi cation of novel mechanisms of maternal vascular remodeling.
